An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development

Toxicologic Pathology

Volumn 38, Issue 1, 2010, Pages 51-61

  Storer, Richard D ^a   Sistare, Frank D ^a   Reddy, M Vijayaraj ^a   Degeorge, Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Carcinogenicity; Mice; Pharmaceuticals; Testing; Transgenic; Utility

Indexed keywords

AMPICILLIN; BENZENE; CHLOROFORM; CHLORPROMAZINE; CLOFIBRATE; COLESTYRAMINE; CYCLOPHOSPHAMIDE; DIELDRIN; DIETHANOLAMINE; DIMETHYLNITROSAMINE; GLYCIDOL; HALOPERIDOL; MANNITOL; MELPHALAN; OLEIC ACID; ORCIPRENALINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PHENACETIN; PHENOBARBITAL; PHENOLPHTHALEIN; PROCARBAZINE; PROTEIN P53; RESERPINE; RESORCINOL; ROTENONE; SULFAFURAZOLE; SULFAMETHOXAZOLE; THIOTEPA; UNINDEXED DRUG; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

CANCER MODEL; CANCER SUSCEPTIBILITY; CARCINOGEN TESTING; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; DRUG RESEARCH; GENOTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SAFETY; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG TOXICITY; HUMAN; METHODOLOGY; MOUSE; PHYSIOLOGY; RAT;

ANIMALIA; MUS; MUS MUSCULUS; RATTUS; RODENTIA;

ANIMALS; CARCINOGENICITY TESTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; MICE; MICE, TRANSGENIC; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952306315     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623309351718     Document Type: Review

References (82)

1. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (London) 318, 533-538
2. Ando, K., Saitoh, A., Hino, O., Takahashi, R., Kimura, M., and Katsuki, M. (1992). Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res 52, 978-982
3. Anisimov, V. N., Ukraintseva, S. V., and Yashin, A. I. (2005). Cancer in rodents: Does it tell us about cancer in humans? Nat Rev Cancer 5, 807-819
4. Ashby J. (2001). Expectations for transgenic rodent cancer bioassay models. Toxicol Pathol 29, 177-182
5. Berg R. J., de Vries, A., van Steeg, H., and de Gruijl, F. R. (1997). Relative susceptibilities of XPA knockout mice and their heterozygous and wild-type littermates to UVB-induced skin cancer. Cancer Res 57, 581-584
6. Boley, S. E., Anderson, E. E., French, J. E., Donehower, L. A., Walker, D. B. and Recio, L. (2000). Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: Evidence of chromosomal recombination. Cancer Res 60, 2831-2835
7. Breuer, M., Slebos, R., Verbeek, S. van Lohuizen, M., Wientjens, E., and Berns, A. (1989). Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature (London) 340, 61-63.
8. Carmichael, N. G., Debruyne, E. L., and Bigot-Lasserre, D. (2000). The p53 heterozygous knockout mouse as a model for chemical carcinogenesis in vascular tissue. Environ Health Perspect 108, 61-65.
9. Cohen, S. M. (2001). Alternative models for carcinogenicity testing: Weight of evidence evaluations across models. Toxicol Pathol 29, 183-190
10. Cohen, S.M., Storer, R. D., Criswell, K. A., Doerrer, N. G., Dellarco, V. L., Pegg, D. G., Wojcinski, Z. W., Malarkey, D. E., Jacobs, A. C., Klaunig, J. E., Swenberg, J. A., and Cook, J. C. (2009). Hemangiosarcoma in rodents: Mode-of-action evaluation and human relevance. Toxicol Sci 111, 4-18.
11. Contrera J. F., and DeGeorge, J. J. (1998). In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ Health Perspect 106 (Suppl 1), 71-80.
12. Cui, Q., Ma, Y., Jaramillo, M., Bari, H., Awan, A., Yang, S., Zhang, S., Liu, L., Lu, M., O'Connor-McCourt, M., Purisima, E. O., and Wang, E. (2007). A map of human cancer signaling. Mol Syst Biol 3, 1-13.
13. Dennis, C. (2006) Cancer: Off by a whisker. Nature 442, 739-741
14. de Vries, A, van Oostrom C. T., Hofhuis, F. M., Dortant, P. M., Berg, R. J., de Gruijl, F. R., Wester, P. W., van Kreijl, C. F., Capel, P. J., and van Steeg, H. (1995). Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377, 169-173
15. de Vries, A., and van Steeg, H. (1996). Xpa knockout mice. Semin Cancer Biol 7, 229-240
16. de Vries, A., van Oostrom, C. T., Dortant, P. M., Beems, R. B., van Kreijl, C. F., Capel, P. J., and van Steeg, H. (1997) Spontaneous liver tumors and benzo[a]pyrene-induced lymphomas in XPA-deficient mice. Mol Carcinog 19, 46-53.
17. de Vries, A., Dollé, M. E., Broekhof, J. L., Muller, J. J., Kroese, E. D., van Kreijl, C. F., Capel, P. J., Vijg, J., and van Steeg, H. (1997). Induction of DNA adducts and mutations in spleen, liver and lung of XPAdeficient/ lacZ transgenic mice after oral treatment with benzo[a]pyrene: Correlation with tumour development. Carcinogenesis 18, 2327-2332
18. de Vries, A., van Steeg, H., and Opperhuizen, A. (2004). Transgenic mice as alternatives in carcinogenicity testing: Current status. RIVM report 340700001. Available at http://rivm.openrepository.com/rivm/bitstream/10029/ 8911/1/340700001.pdf. Accesse 14 October 2009.
19. Dolinoy, D. C., Huang, D., and Jirtle, R. L. (2007). Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci U S A 104, 13056-13061
20. Donehower, L. A. (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin Cancer Biol 7, 269-278
21. Donehower, L. A., Harvey, M., Slagle, B. L.,McArthur, M. J.,Montgomery, C. A. Jr, Butel, J. S., and Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356, 215-221
22. Dunnick, J. K., Hardisty, J. F., Herbert, R. A.,Seely, J. C., Furedi-Machacek, E. M., Foley, J. F., Lacks, G. D., Stasiewicz, S., and French, J. E. (1997). Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice. Toxicol Pathol 25, 533-540
23. Eastin, W. C., Haseman, J. K., Mahler, J. F., and Bucher, J. R. (1998). The National Toxicology Program evaluation of genetically altered mice as predictive models for identifying carcinogens. Toxicol Pathol 26, 461-473
24. Eastin, W. C., Mennear, J. H., Tennant, R. W., Stoll, R. E., Branstetter, D. G., Bucher, J. R., McCullough, B., Binder, R. L., Spalding, J. W., and Mahler, J. F. (2001). Tg.AC genetically altered mouse: Assay working group overview of available data. Toxicol Pathol 29 (Suppl), 60-80.
25. French, J. E., Lacks, G. D., Trempus, C., Dunnick, J. K., Foley, J., Mahler, J., Tice, R. R. and Tennant, R. W. (2001b). Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogenand tissue-dependent. Carcinogenesis 22, 99-110
26. French, J., Storer, R. D., and Donehower, L. A. (2001a). The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol 29 (Suppl), 24-29.
27. Frese, K. K., and Tuveson, D. A. (2007). Maximizing mouse cancer models. Nat Rev Cancer 7, 645-658
28. Graeber, T. G., and Sawyers, C. L. (2005). Cross-species comparisons of cancer signaling Nat Genet 37, 7-8.
29. Hahn, W. C., and Weinberg, R. A. (2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer 2, 331-341
30. Harvey, M., McArthur, M. J., Montgomery, C. A. Jr, Butel, J. S., Bradley, A., and Donehower, L. A. (1993a) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5, 225-229
31. Harvey, M., McArthur, M. J., Montgomery, C. A. Jr, Bradley, A., and Donehower, L. A. (1993b). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7, 938-943
32. Harvey M., Vogel. H., Morris, D., Bradley, A., Bernstein, A., Donehower, L. A. (1995) mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9, 305-311
33. Honchel, R., Rosenzweig, B. A., Thompson, K. L., Blanchard, K. T., Furst, S. M., Stoll, R. E., and Sistare, F. D. (2001). Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype. Mol Carcinog 30, 99-110.
34. International Committee on Harmonization (1998). Guidance on testing for carcinogenicity of pharmaceuticals. Fed Reg 63, 8983-8986
35. Jacobs, A. (2005) Prediction of 2-year carcinogenicity study results for pharmaceutical products: How are we doing? Toxicol Sci 88, 18-23.
36. Jacobsen-Kram, D. (2008) Commentary: Regulatory toxicology and the critical path: Predicting long-term outcomes from short-term studies. Vet Pathol 45, 707-709
37. Jacobson-Kram, D., Sistare, F. D., and Jacobs, A. C. (2004). Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol 32 (Suppl 1), 49-52.
38. Jiang, W., Ananthaswamy, H. N., Muller, H. K., and Kripke, M. L. (1999). p53 protects against skin cancer induction by UV-B radiation. Oncogene 18, 4247-4253
39. Jiang, W., Ananthaswamy, H. N., Muller, H. K., Ouhtit, A., Bolshakov, S., Ullrich, S. E., El-Naggar, A. K., and Kripke, M. L. (2001). UV irradiation augments lymphoid malignancies in mice with one functional copy of wild-type p53. Proc Natl Acad Sci U S A 98, 9790-9795
40. Jin, M., Takahashi, M., Moto, M., Muguruma, M., Ito, K., Watanabe, K., Kenmochi, Y., Kono, T., Hasumi, K., and Mitsumori, K. (2007). Carcinogenic susceptibility of rasH2 mice to troglitazone. Arch Toxicol 81, 883-894
41. Kemp, C. J., Donehower, L. A., Bradley, A., and Balmain, A. (1993). Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74, 813-822
42. Kemp, C. J., Wheldon, T., and Balmain, A. (1994). p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8, 66-69.
43. Leder, A., Kuo, A., Cardiff, R. D., Sinn, E., and Leder, P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effects of phorbol esters and retinoic acid. Proc Natl Acad Sci U S A 87, 9178-9182
44. Lee, J. S., Chu, I. S., Mikaelyan, A., Calvisi, D. F., Heo, J., Reddy, J. K., and Thorgeirsson, S. S. (2004). Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36, 1306-1311
45. MacDonald, J., French, J. E., Gerson, R. J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F. D., Storer, R., and van der Laan, J.W. (2004). The utility of genetically modified mouse assays for identifying human carcinogens:A basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci 77, 188-194
46. McClain, R. M., Keller, D., Casciano, D., Fu, P., MacDonald, J., Popp, J., Sagartz, J. (2001). Neonatal mouse model: Review of methods and results. Toxicol Pathol 29 (Suppl), 128-137
47. Mitsumori, K., Wakana, S., Yamamoto, S., Kodama, Y., Yasuhara, K., Nomura, T., Hayashi, Y., and Maronpot, R. R. (1997). Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a shortterm carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors. Mol Carcinog 20, 298-307.
48. Mitsumori, K., Koizumi, H., Nomura, T., and Yamamoto, S. (1998). Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol 26, 520-531
49. Morton, D., Alden, C. L., Roth, A. J., and Usui, T. (2002). The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol 30, 139-146
50. Ozaki, K., Sukata, T., Yamamoto, S., Uwagawa, S., Seki, T., Kawasaki, H., Yoshitake, A., Wanibuchi, H., Koide, A., Mori, Y., and Fukushima, S. (1998). High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl) nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 58, 3806-3811
51. Ozaki, M., Ozaki, K., Watanabe, T., Uwagawa, S., Okuno, Y., and Shirai, T. (2005). Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains. Toxicol Pathol 33, 267-271
52. Paranjpe, M., Wenk, M., and Smith, G. (2008). Transgenic rasH2 mouse: A Model for Dermal Carcinogenesis. Available at http://www.taconic.com/user- assets/Documents/streaming-media/paranjpe-ppt.pdf. Accesse 13 October 2009.
53. Pritchard, J. B., French, J. E., Davis, B. J., and Haseman, J. K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 444-454
54. Qin, C.,Wang, Z., Shang, J., Bekkari, K., Liu, R., Pacchione, S., McNulty, K.A., Ng, A., Barnum, J. E., and Storer, R. D. (forthcoming). Intracisternal A particle genes: Distribution in the mouse genome, acitver subtypes, and potential roles as species-specific mediators of susceptibility to cancer. Mol Carcinog.
55. Rangarajan, A., and Weinberg, R. A. (2003). Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer 3, 952-959
56. Reddy, V. (2007). Evaluation of six- and twelve-month rat toxicity assay as predictors of tumorigenicity. Drug Information Association 43rd Annual Meeting Session 273. Available at http://www.softconference.com/270617. Accesse 13 October 2009.
57. Robinson, D. E., and MacDonald, J. S. (2001). Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute. Toxicol Pathol 29 (Suppl), 13-19.
58. Saitoh, A., Kimura, M., Takahashi, R., Yokoyama, M., Nomura, T., Izawa, M., Sekiya, T., Nishimura, S., and Katsuki, M. (1990). Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5, 1195-1200
59. Schwetz, B., and Gaylor, D. (1998). Alternative tests: Carcinogenesis as an example. Environ Health Perspect 106 (Suppl 2), 467-471
60. Spalding, J. W., Momma, J., Elwell, M. R., and Tennant, R. W. (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. Carcinogenesis 14, 1335-1341
61. Spalding, J. W., French, J. E., Stasiewicz, S., Furedi-Machacek, M., Conner, F., Tice, R. R., and Tennant, R. W. (2000). Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. Toxicol Sci 53, 213-223
62. Storer, R. D., Cartwright, M. E., Cook, W. O., Soper, K. A., and Nichols,W. W. (1995). Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice. Carcinogenesis 16, 285-293
63. Storer, R. D., French, J. E., Haseman, J., Hajian, G., LeGrand, E. K., Long, G. G., Mixson, L. A., Ochoa, R., Sagartz, J. E., and Soper, K. A. (2001). p53+/-hemizygous knockout mouse: Overview of available data. Toxicol Pathol 29 (Suppl), 30-50.
64. Tamaoki, N. (2001). The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol 29 (Suppl 1), 81-89.
65. Tennant R. W., Rao, G. N., Russfield, A., Seilkop, S., and Braun, A. G. (1993). Chemical effects in transgenic mice bearing oncogenes expressed in mammary tissue. Carcinogenesis 14, 29-35.
66. Tennant, R. W., French, J. E., and Spalding, J. W. (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103, 942-950
67. Tennant, R. W., Stasiewicz, S., Mennear, J., French, J. E., and Spalding, J. W. (1999). Genetically altered mouse models for identifying carcinogens. IARC Sci Publ 146, 123-150
68. Tennant, R.W., Stasiewicz, S., Eastin, W. C.,Mennear, J. H., and Spalding, J. W. (2001). The Tg.AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol Pathol 29 (Suppl), 51-59.
69. Thompson, K. L., Rosenzweig, B. A., and Sistare, F. D. (1998). An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness. Toxicol Pathol 26, 548-555
70. Thompson, K. L., Rosenzweig, B. A., Honchel, R., Cannon, R. E., Blanchard, K. T., Stoll, R. E., and Sistare, F. D. (2001). Loss of critical palindromic transgene promoter sequence in chemically induced Tg.AC mouse skin papillomas expressing transgene-derived mRNA. Mol Carcinog 32, 176-186
71. Torti, V. R., Cobb, A. J., Everitt, J. I., Marshall, M. W., Boorman, G. A., and (2001). A comparison of toxicity and tumorigenesis in two strains of p53-heterozygous mice: The response to inhaled bromodichloromethane. Toxicol Pathol 29 (Suppl), 232-233
72. Usui, T., Mutai, M., Hisada, S., Takoaka, M., Soper, K. A., McCullough, B., and Alden, C. (2001). CB6F1-rasH2 mouse: Overview of available data. Toxicol Pathol 29 (Suppl), 90-108.
73. van Kriejl, C. F., McAnulty, P. A., Beems, R. B., Vynckier, A., van Steeg, H., Fransson-Steen, R., Alden, C. L., Forster, R., van der Laan, J-W., and Vandenberghe, J. (2001). XPA and XPA/p53+/- knockout mice: Overview of available data. Toxicol Pathol 29 (Suppl), 117-127
74. van Lohuizen, M., Verbeek, S., Krimpenfort, P., Domen, J., Saris, C., Radaszkiewicz, T., and Berns, A. (1989). Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56, 673-682
75. van Steeg, H., de Vries, A., van Oostrom, C. T. M., van Benthem, J., Beems, R. B., and van Kriejl, C. F. (2001). DNA repair-deficient XPA and XPA/p53+/-knock-out mice: Nature of the models. Toxicol Pathol 29 (Suppl), 109-116
76. Waterland, R. A. and Jirtle, R. L. (2003) Transposable elements: Targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 15, 5293-5300
77. Yamamoto, S., Mitsumori, K., Kodama,Y., Matsunuma, N., Manabe, S., Okamiya, H., Suzuki, H., Fukuda, T., Sakamaki, Y., Sunaga, M., Nomura, G., Hioki, K., Wakana, S., Nomura, T., and Hayashi, Y. (1996). Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis 17, 2455-2461
78. Yamamoto, S., Hayashi, Y., Mitsumori, K., and Nomura, T. (1997). Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene. Lab Anim Sci 47, 121-126
79. Yamamoto, S., Urano, K., Koizumi, H., Wakana, S., Hioki, K., Mitsumori, K., Kurokawa, Y., Hayashi, Y., and Nomura, T. (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect 106 (Suppl 1), 57-69. (Pubitemid 28196036)
80. Yamamoto, S., Urano, K., and Nomura, T. (1998). Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol Lett 102-103, 473-478 (Pubitemid 29021264)
81. Yamamoto, M., Tsukamoto, T., Sakai, H., Shirai, N., Ohgaki, H., Furihata, C., Donehower, L. A., Yoshida, K., and Tatematsu, M. (2000). p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis. Carcinogenesis 21, 1891-1897
82. Zhang, Y., Maksakova, I. A., Gagnier, L., van de Lagemaat, L. N., and Mager, D. L. (2008). Genome-wide assessments reveal extremely high levels of polymorphism of two active families of mouse endogenous retroviral elements. PLoS Genet 4 (2), e1000007.